Wimmer Associates 1’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.33M | Sell |
11,064
-961
| -8% | -$111K | 0.65% | 39 |
|
|
2025
Q4 | $1.27M | Sell |
12,025
-108
| -0.9% | -$10.1K | 0.59% | 40 |
|
|
2025
Q3 | $1.02M | Sell |
12,133
-439
| -3% | -$36.2K | 0.49% | 53 |
|
|
2025
Q2 | $995K | Sell |
12,572
-615
| -5% | -$48.9K | 0.51% | 52 |
|
|
2025
Q1 | $1.01M | Sell |
13,187
-1,015
| -7% | -$94.8K | 0.53% | 49 |
|
|
2024
Q4 | $1.41M | Sell |
14,202
-740
| -5% | -$76.3K | 0.7% | 36 |
|
|
2024
Q3 | $1.7M | Buy |
14,942
+295
| +2% | +$35K | 0.83% | 31 |
|
|
2024
Q2 | $1.81M | Sell |
14,647
-45
| -0.3% | -$5.8K | 0.93% | 29 |
|
|
2024
Q1 | $1.94M | Buy |
14,692
+15
| +0.1% | +$1.85K | 1.02% | 30 |
|
|
2023
Q4 | $1.6M | Sell |
14,677
-385
| -3% | -$40K | 0.9% | 32 |
|
|
2023
Q3 | $1.55M | Sell |
15,062
-270
| -2% | -$29.1K | 0.97% | 32 |
|
|
2023
Q2 | $1.77M | Hold |
15,332
| – | – | 1.06% | 29 |
|
|
2023
Q1 | $1.78M | Sell |
15,332
-1,504
| -9% | -$162K | 1.14% | 29 |
|
|
2022
Q4 | $1.87M | Buy |
16,836
+127
| +0.8% | +$13K | 1.23% | 27 |
|
|
2022
Q3 | $1.69M | Buy |
16,709
+417
| +3% | +$37.2K | 1.12% | 28 |
|
|
2022
Q2 | $1.49M | Sell |
16,292
-625
| -4% | -$55.4K | 0.97% | 34 |
|
|
2022
Q1 | $1.39M | Buy |
16,917
+240
| +1% | +$18.9K | 0.77% | 39 |
|
|
2021
Q4 | $1.28M | Sell |
16,677
-575
| -3% | -$45.8K | 0.69% | 44 |
|
|
2021
Q3 | $1.3M | Sell |
17,252
-1,305
| -7% | -$99.3K | 0.77% | 40 |
|
|
2021
Q2 | $1.44M | Sell |
18,557
-330
| -2% | -$24.5K | 0.85% | 37 |
|
|
2021
Q1 | $1.39M | Buy |
18,887
+246
| +1% | +$18.1K | 0.76% | 37 |
|
|
2020
Q4 | $1.46M | Buy |
18,641
+470
| +3% | +$35.9K | 0.87% | 33 |
|
|
2020
Q3 | $1.44M | Buy |
18,171
+414
| +2% | +$32.4K | 0.97% | 32 |
|
|
2020
Q2 | $1.37M | Sell |
17,757
-1,054
| -6% | -$79.3K | 1.07% | 32 |
|
|
2020
Q1 | $1.39M | Buy |
18,811
+2,238
| +14% | +$176K | 1.29% | 28 |
|
|
2019
Q4 | $1.44M | Buy |
16,573
+310
| +2% | +$25.5K | 1.15% | 30 |
|
|
2019
Q3 | $1.31M | Buy |
16,263
+4,624
| +40% | +$371K | 1.14% | 33 |
|
|
2019
Q2 | $931K | Sell |
11,639
-84
| -0.7% | -$6.43K | 0.81% | 43 |
|
|
2019
Q1 | $930K | Hold |
11,723
| – | – | 0.82% | 42 |
|
|
2018
Q4 | $855K | Buy |
11,723
+325
| +3% | +$22.9K | 0.85% | 41 |
|
|
2018
Q3 | $772K | Buy |
11,398
+288
| +3% | +$18.3K | 0.64% | 49 |
|
|
2018
Q2 | $643K | Buy |
11,110
+3,238
| +41% | +$183K | 0.57% | 53 |
|
|
2018
Q1 | $409K | Buy |
7,872
+1,490
| +23% | +$80.5K | 0.36% | 76 |
|
|
2017
Q4 | $343K | Buy |
6,382
+451
| +8% | +$25K | 0.31% | 84 |
|
|
2017
Q3 | $362K | Buy |
5,931
+175
| +3% | +$10.6K | 0.33% | 81 |
|
|
2017
Q2 | $352K | Sell |
5,756
-656
| -10% | -$39.9K | 0.32% | 81 |
|
|
2017
Q1 | $389K | Sell |
6,412
-819
| -11% | -$49.7K | 0.36% | 80 |
|
|
2016
Q4 | $406K | Buy |
7,231
+1,372
| +23% | +$80.3K | 0.38% | 76 |
|
|
2016
Q3 | $349K | Hold |
5,859
| – | – | 0.31% | 85 |
|
|
2016
Q2 | $322K | Buy |
5,859
+721
| +14% | +$38.4K | 0.29% | 89 |
|
|
2016
Q1 | $259K | Buy |
+5,138
| New | +$252K | 0.24% | 94 |
|
Other funds holding MRK
VCM
VPM
Wimmer Associates 1's MRK Position: Q1 2026 in Review
Wimmer Associates 1 reduced its Merck (MRK) stake by 8% in Q1 2026, selling an estimated $111K and leaving 11,064 shares worth $1.33M. The position accounts for 0.65% of the portfolio, ranked #39.
Wimmer Associates 1 first reported a position in MRK in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.94M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Wimmer Associates 1 held 11,064 shares of Merck worth $1.33M as of Q1 2026.
- Wimmer Associates 1 sold 961 Merck shares in Q1 2026, an estimated $111K.
- Merck made up 0.65% of Wimmer Associates 1's portfolio in Q1 2026, its #39 holding.
- Wimmer Associates 1 first reported a position in Merck in Q1 2016 and has held it in 41 quarters since.
- Wimmer Associates 1's Merck position peaked at $1.94M in Q1 2024.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Wimmer Associates 1's 13F filing for Q1 2026, filed 15 May 2026.